James V. Lacey, Jr., Ph.D., M.P.H.
- Epidemiologic Cohort Studies
- Population-health Informatics
- Expansion of the California Teachers Study
- Risk Factors of Gynecologic Cancers
- Post Menopausal Hormone Use and Cancer Risk
Dr. Lacey is the director of the Division of Health Analytics within the Department of Computational and Quantitative Medicine at Beckman Research Institute of City of Hope and serves as Principal Investigator for the California Teachers Study project.
Lacey’s work has been key in demonstrating that women using menopausal progestins and estrogens are more likely to develop uterine and ovarian cancer. He is continuing to investigate how hormones affect the risk of developing uterine cancer, ovarian cancer, breast cancer and other diseases among women.
Dr. Lacey received his Ph.D. from the Horace H. Rackham School of Graduate Studies of the University of Michigan. After completing a postdoctoral fellowship at the National Cancer Institute (NCI), Dr. Lacey was an Investigator in the NCI’s Division of Cancer Epidemiology and Genetics from 2001 to 2009. He joined the faculty at City of Hope in 2009; his primary research interest is the epidemiology of breast, uterine, and ovarian cancers.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
1998, University of Michigan, Horace H. Rackham School of Graduate Studies, Ann Arbor, MI, Ph.D., Epidemiologic Science
1995, University of Michigan, School of Public Health, Ann Arbor, MI, M.P.H., Epidemiology
1993, University of Michigan, College of Literature, Science, and the Arts, Ann Arbor, MI, B.S., Psychology as a Natural Science
1998 - 2001, Cancer Research Training Award, Environmental Epidemiology Branch [now Metabolic Epidemiology Branch (MEB)], Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Bethesda, MD
2018 - present, Professor and Director, Division of Health Analytics, Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, CA
2017 - 2018, Professor, Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA
2016 - present, Associate Professor, Center for Gene Therapy, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, Duarte, CA
2016 - 2018, Director, Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA
2015 - 2017, Faculty Collaboration Strategist, Department of Information Technology Services, City of Hope, Duarte, CA
2010 - present, Member, Cancer Control and Population Sciences Program, City of Hope Comprehensive Cancer Center, Duarte, CA
2009 - 2016, Associate Professor, Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA
2001 - 2009, Investigator (Tenure-Track), HREB, DCEG, NCI, Bethesda, MD
Awards & Memberships
Awards
2018, Salesforce Healthcare Research Trailblazer Award
2005, DCEG Intramural Research Award, Bethesda, MD
2005, NIH Award of Merit, Bethesda, MD
2003, DCEG Most Cited Paper in 2002 Award, NCI, NIH, Bethesda, MD
2001, Fellows Award for Research Excellence, NCI, NIH, Bethesda, MD
2000, Division of Cancer Epidemiology & Genetics (DCEG), Fellowship Achievement Award, NCI, NIH, Bethesda, MD
Memberships
2015 - present, NCI Board of Scientific Advisors
2014 - present, External Advisory Board, St. Jude Lifetime Cohort, St. Jude Children’s Research Hospital, Memphis, TN
2003 - present, American College of Epidemiology (Member)
2001 - present, Molecular Epidemiology Group, AACR
1999 - present, American Association for Cancer Research (AACR)
Publications
1. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH Jr, Burns CB, Johanns JR, Cooper BC, Keroack BJ, Wasko MCM, Lacey JV Jr, Schottenfeld D. Racial differences in scleroderma among women in Michigan. Arthritis Rheum1997;40:734-42.
2. Lacey JV Jr, Garabrant DH, Laing TJ, Gillespie BW, Mayes MD, Cooper BC, Schottenfeld D. Petroleum distillate solvents as risk factors for undifferentiated connective tissue disease (UCTD). Am J Epidemiol 1999;149:761-70.
3. Lacey JV Jr, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Silverberg SG, Hildesheim A. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas.Cancer Epidemiol Biomarkers Prev 1999;8:1079-85.
4. Lacey JV Jr, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Kurman RJ, Hildesheim A. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000;77:149-54.
5. Lacey JV Jr, Brinton LA, Mortel R, Berman ML, Wilbanks GD, Twiggs LB, Barrett RJ. Tubal sterilization and risk of cancer of the endometrium. Gynecol Oncol 2000;79:482-4.
6. Gravitt PE, Lacey JV Jr, Brinton LA, Barnes W, Kornegay J, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Zaino R, Hildesheim A. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 2001;10:95-100.
7. Laing TJ, Schottenfeld D, Lacey JV Jr, Gillespie BW, Garabrant DH, Cooper BC, Heeringa SG, Alcser KH, Mayes MD. Potential risk factors for undifferentiated connective tissue disease among women: implanted medical devices. Am J Epidemiol 2001;154:610-7.
8. Lacey JV Jr, Frisch M, Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Zaino RJ, Hildesheim A. Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control 2001;12:153-61.
9. Lacey JV Jr, Deng J, Dosemeci M, Gao Y-T, Mostofi FK, Sesterhenn IA, Xie T, Hsing AW. Prostate cancer, benign prostatic hyperplasia, and physical activity in Shanghai, China. Int J Epidemiol 2001;30:341-9.
10. Lacey JV Jr, Hsing AW, Fillmore C-M, Hoffman S, Helzlsouer KJ, Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev 2001;10:1101-2.